Clinical Trials Logo

Idiopathic Peripheral Neuropathy clinical trials

View clinical trials related to Idiopathic Peripheral Neuropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT03401073 Completed - Clinical trials for Small Fiber Neuropathy

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

The objective of this study is to develop a rationale for the selective treatment of small fiber neuropathy with immune globulin (IVIG) in the appropriate patients. The investigators hypothesize that individuals with auto-antibodies targeting neuronal antigens (TS-HDS and FGFR3) and confirmed evidence of small fiber neuropathy (by skin biopsy analysis of intra-epidermal nerve fiber density) will have an improvement in both nerve fiber density and pain after treatment with immune globulin. The co-primary endpoints will be a change in neuropathic pain (by VAS pain score) and a change in intra-epidermal nerve fiber density (by punch skin biopsy). The data gained from this pilot study will establish a rationale, with an appropriate screening test, for the use of immune globulin for the treatment of small fiber neuropathy.

NCT ID: NCT01288937 Terminated - Clinical trials for Idiopathic Peripheral Neuropathy

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

Start date: April 5, 2011
Phase: Phase 3
Study type: Interventional

This is an 11-week randomized, double-blind, placebo-controlled trial of Milnacipran 100 mg/d in patients with idiopathic neuropathic pain. Milnacipran, a dual norepinephrine and serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with fibromyalgia and may be useful to treat patients with painful peripheral neuropathy. The primary outcome will be assessed by the change in daily averaged weekly 0-10 pain intensity score, from baseline to week 9, by intention to treat analysis. The same analysis will be used on several secondary measures including daily averaged weekly 0-10 pain intensity score the sleep interference scale and the Rand-36 quality of life scale.